Last reviewed · How we verify

Furosemide intravenous solution

Lakeland Regional Health Systems, Inc. · FDA-approved active Small molecule

Furosemide inhibits sodium and chloride reabsorption in the ascending loop of Henle, promoting diuresis and reducing fluid volume.

Furosemide inhibits sodium and chloride reabsorption in the ascending loop of Henle, promoting diuresis and reducing fluid volume. Used for Edema associated with congestive heart failure, Edema associated with hepatic cirrhosis, Edema associated with renal disease.

At a glance

Generic nameFurosemide intravenous solution
Also known asLasix
SponsorLakeland Regional Health Systems, Inc.
Drug classLoop diuretic
TargetNa-K-2Cl cotransporter (NKCC2)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Furosemide is a loop diuretic that blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing reabsorption of sodium, potassium, and chloride. This increases urine output and reduces total body fluid volume, thereby decreasing preload on the heart and lowering blood pressure. The intravenous formulation provides rapid onset of action, making it useful in acute settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: